Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines
Name
Sauer_Substrate-guided.pdf
Size
982.45 KB
Format
Adobe PDF
Checksum (MD5)
c1ebe7acf46053762385f781f438f402
Author(s)
Totaro, Kyle A.
Barthelme, Dominik
Simpson, Peter T.
Sello, Jason K.
Sauer, Robert T.
Date Issued
July 2015
Journal
Bioorganic & Medicinal Chemistry
Publisher
Elsevier
Citation
Totaro, Kyle A. et al. “Substrate-Guided Optimization of the Syringolins Yields Potent Proteasome Inhibitors with Activity Against Leukemia Cell Lines.” Bioorganic & Medicinal Chemistry 23, 18 (September 2015): 6218–6222 © 2015 Elsevier Ltd
Version
Author's final manuscript
Abstract
Natural products that inhibit the proteasome have been fruitful starting points for the development of drug candidates. Those of the syringolin family have been underexploited in this context. Using the published model for substrate mimicry by the syringolins and knowledge about the substrate preferences of the proteolytic subunits of the human proteasome, we have designed, synthesized, and evaluated syringolin analogs. As some of our analogs inhibit the activity of the proteasome with second-order rate constants 5-fold greater than that of the methyl ester of syringolin B, we conclude that the substrate mimicry model for the syringolins is valid. The improvements in in vitro potency and the activities of particular analogs against leukemia cell lines are strong bases for further development of the syringolins as anti-cancer drugs.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.bmc.2015.07.041
